Drug
Epirubicin clinical trials
Also written Ellence and Farmorubicin.
- studies test it
- 157
- open now
- 16
- in phase 3
- 50
- first study started
- 1991
Keep track of what changes. Save the Epirubicin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Combined with it in one product
Studies by the year they started
155 studies that test it; most in 2001 (11)
| Year | Studies |
|---|---|
| 1991 | 1 |
| 1993 | 1 |
| 1996 | 5 |
| 1997 | 2 |
| 1998 | 3 |
| 1999 | 2 |
| 2000 | 8 |
| 2001 | 11 |
| 2002 | 11 |
| 2003 | 11 |
| 2004 | 7 |
| 2005 | 4 |
| 2006 | 6 |
| 2007 | 9 |
| 2008 | 11 |
| 2009 | 5 |
| 2010 | 4 |
| 2011 | 8 |
| 2012 | 3 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 5 |
| 2017 | 5 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 5 |
| 2023 | 4 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 23
- Phase 2
- 88
- Phase 3
- 50
- Phase 4
- 5
- No phase
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 151
Fudan University (7) · Hellenic Oncology Research Group (5) · Henan Cancer Hospital (4) · Cancer Trials Ireland (4) · Royal Marsden NHS Foundation Trust (4) · NCIC Clinical Trials Group (3) · NSABP Foundation Inc (3) · SCRI Development Innovations, LLC (3)
Often tested with
Tested in the same studies.
Cyclophosphamide (53) · Docetaxel (46) · Paclitaxel (37) · Fluorouracil (24) · Capecitabine (21) · Cisplatin (20) · Carboplatin (19) · Trastuzumab (11)
Studies
Open first, then newest update. How each study uses Epirubicin is read from its arms, and is right about nine times in ten.
Testing it · 157
- Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived OrganoidsNot yet recruitingPhase 2Hospital Centre Biel/BienneNCT06227065Written as Epirubicin
- Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic CarcinomaNot yet recruitingPhase 2Eye & ENT Hospital of Fudan UniversityNCT07616141Written as Anlotinib + Epirubicin
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as Epirubicin
- Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective StudyRecruitingPhase 2Eye & ENT Hospital of Fudan UniversityNCT07320508Written as Epirubicin (E)
- MicroRNA Profiles in Triple Negative Breast CancerRecruitingPhase 2University College Hospital, IbadanNCT04771871Written as Epirubicin
- Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast CancerRecruitingPhase 2University of ChicagoNCT06291064Written as Epirubicin
- A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast CancerRecruitingPhase 3Fudan UniversityNCT05862064Written as epirubicin,cyclophosphamide,paclitaxel,Carrelizumab
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingPhase 2Peking University Shenzhen HospitalNCT06692491Written as Epirubicin
- A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of BreastRecruitingPhase 1Shanghai Jiao Tong University School of MedicineNCT02897700Written as cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM)
- Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast CancerRecruitingPhase 2RemeGen Co., Ltd.NCT06227117Written as Sequential Epirubicin
- Epirubicin for the Treatment of Sepsis & Septic ShockRecruitingPhase 2Jena University HospitalNCT05033808Written as Epirubicin
- Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast CancerRecruitingPhase 1Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06121570Written as Epirubicin
- A Study for the Adjuvant Treatment of Breast CancerRecruitingPhase 4Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05420467Written as Epirubicin
- A Study for the Neoadjuvant Treatment of Breast CancerRecruitingPhase 4Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05420454Written as Epirubicin
- Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer PatientsRecruitingPhase 1/2Peking University People's HospitalNCT04836156Written as neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer
- A Study of Genetic Based Chemotherapy Dosing for Breast Cancer PatientsRecruitingPhase 2AHS Cancer Control AlbertaNCT01740271Written as Epirubicin
- Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived OrganoidsActive, not recruitingPhase 2Roland Seiler-BlarerNCT05024734Written as Epirubicin
- VR-CAP in the First-line Treatment for Patients With Marginal Zone LymphomaCompletedPhase 2Henan Cancer HospitalNCT04433156Written as Epirubicin
- Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast CancerCompletedPhase 1/2NCIC Clinical Trials GroupNCT00066443Written as epirubicin hydrochloride
- Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's LymphomaActive, not recruitingPhase 2Henan Cancer HospitalNCT04067037Written as Epirubicin
See all 157 studies that test Epirubicin →
Given in every arm · 122 — Epirubicin is usual care beside what is tested
- Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast CancerRecruitingPhase 2Henan Cancer HospitalNCT06860529Written as Epirubicin
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06966700Written as Epirubicin
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06797635Written as Epirubicin hydrochloride
- Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell LymphomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07753642Written as Epirubicin
- Neoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Negative Breast CancerRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06964906Written as Epirubicin (E)
- A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerRecruitingPhase 3Shanghai JMT-Bio Inc.NCT07441460Written as Epirubicin
- Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBCRecruitingPhase 2Vandana AbramsonNCT07016399Written as Epirubicin
- Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple MyelomaRecruitingPhase 2Wuhan Union Hospital, ChinaNCT06140966Written as epirubicin
- ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.Not yet recruitingPhase 1Hansoh BioMedical R&D CompanyNCT06699576Written as Epirubicin
- To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast CancerNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06470633Written as Epirubicin
- To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast CancerRecruitingPhase 2RemeGen Co., Ltd.NCT06389006Written as Epirubicin
- QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT06404463Written as Epirubicin
- Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant ChemotherapyRecruitingPhase 2wang shusenNCT05978648Written as Epirubicin
- Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast CancerNot yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT05983094Written as Epirubicin
- Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast CancerRecruitingPhase 1/2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05981014Written as Epirubicin
- Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk FactorsNot yet recruitingPhase 2Liaoning Cancer Hospital & InstituteNCT05887726Written as Epirubicin
- Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)RecruitingPhase 2West China HospitalNCT05447702Written as Epirubicin
- Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast CancerRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT05834582Written as Epirubicin+Cyclophosphamide
- AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFHEnrolling by invitationPhase 3Tianjin Medical University Cancer Institute and HospitalNCT05678933Written as Epirubicin
- Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world StudyNot yet recruitingNot applicableChinese Academy of Medical SciencesNCT05287308Written as epirubicin
Showing 20 of 122.
As the comparator · 46 — what is tested is compared with Epirubicin
- TCb vs EC-T in High Risk ER+/HER2- Breast CancerRecruitingPhase 3Fudan UniversityNCT05901428Written as Epirubicin
- A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBCRecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07424287Written as Epirubicin Hydrochloride for Injection
- Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）RecruitingPhase 2Hebei Medical University Fourth HospitalNCT06107673Written as Epirubicin Hydrochloride Injection
- Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast CancerRecruitingPhase 2Hebei Medical University Fourth HospitalNCT04138719Written as Nab-paclitaxel + Epirubicin
- Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast CancerRecruitingPhase 2Karolinska University HospitalNCT05900206Written as Epirubicin
- Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer PatientsNot yet recruitingPhase 3Fudan UniversityNCT06795503Written as Epirubicin, cyclophosphamide plus paclitaxel
- EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast CancerRecruitingPhase 3Fudan UniversityNCT05883852Written as Epirubicin
- The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.Not yet recruitingPhase 2Peng LiuNCT05816694Written as Cisplatin plus Epirubicin plus Cyclophosphamide
- To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical StudyRecruitingNot applicableShanghai Pudong HospitalNCT05656079Written as Epirubicin
- A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC PatientsRecruitingPhase 3Jiangsu Yahong Meditech Co., Ltd aka AsierisNCT04736394Written as Epirubicin Hydrochloride
- Combination Therapy of Anthracyclines for Children With NephroblastomaNot yet recruitingPhase 4Shengjing HospitalNCT03892330Written as Pharmorubicin
- Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast CancerActive, not recruitingPhase 3Fudan UniversityNCT04193059Written as Epirubicin
- Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant ChemotherapyCompletedPhase 3Italian Sarcoma GroupNCT01710176Written as epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3)
- Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)Active, not recruitingPhase 3Fudan UniversityNCT04296175Written as Epirubicin
- ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBCActive, not recruitingPhase 2Sun Yat-sen UniversityNCT04172259Written as Epirubicin
- TACE With Dicycloplatin(TP21) in Unresectable HCCStatus unknownPhase 3Gao-jun TengNCT05472896Written as Epirubicin
- Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal WomenCompletedPhase 2UNICANCERNCT02400567Written as Epirubicin
- A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer PatientsStatus unknownPhase 2TTY BiopharmNCT01210768Written as Epirubicin+Cyclophosphamide
- The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric CancerCompletedPhase 3Fudan UniversityNCT02395640Written as Epirubicin
- A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast CancerCompletedPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT02742051Written as Epirubicin
Showing 20 of 46.
Codes
What other systems call Epirubicin · ClinicalTrials.gg INT008452
- MeSH (NLM) D015251EpirubicinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 3Z8479ZZ5XEPIRUBICINConfirmed FDA, NLM, Wikidata
- RxNorm 3995Confirmed FDA, Wikidata
- Wikidata Q425122epirubicinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C62028EpirubicinOne source FDA
- DrugBank DB00445One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D015251 | Epirubicin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 3Z8479ZZ5X | EPIRUBICIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 3995 | — | Confirmed FDA, Wikidata |
| Wikidata | Q425122 | epirubicin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C62028 | Epirubicin | One source FDA |
| DrugBank | DB00445 | — | One source Wikidata |
Also registered as epirubicin hydrochloride (UNII 22966TX7J5 · RxNorm 203213).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.